We are live on ! Find out more
OM icon

Outset Medical

113 hedge funds and large institutions have $112M invested in Outset Medical in 2024 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $575K | Put options by funds: $363K

5.62% less ownership

Funds ownership: 105.58% → 99.95% (-5.6%)

17% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 41

19% less funds holding

Funds holding: 139 → 113 (-26)

40% less capital inflows, than outflows

Capital inflows: $27M | Capital outflows: $44.7M

74% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 34

Holders
113
Holders Change
-26
Holders Change %
-18.71%
% of All Funds
1.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
34
Reduced
41
Closed
34
Calls
$575​K
Puts
$363​K
Net Calls
+$212​K
Net Calls Change
+$3.1​M

OM Hedge Fund Activity: Q1 2024 in Review

113 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q1 2024, worth a combined $112M — down 61% from $287M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of OM and 9 opened new positions — a net loss of 25 holders — while 41 trimmed existing stakes and 34 added.

The largest buyer was Ameriprise, adding an estimated $7.19M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $17.1M sold.

  • 113 institutional investors held Outset Medical (OM) as of Q1 2024, down from 139 in Q4 2023.
  • Funds reported $112M of Outset Medical stock for Q1 2024, down 61% quarter-over-quarter.
  • 9 funds opened new Outset Medical positions in Q1 2024 and 34 closed out, a net change of -25 holders.
  • The largest Outset Medical buyer in Q1 2024 was Ameriprise, an estimated $7.19M added.
  • The largest Outset Medical seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q1 2024.